Join the Rybelsus group to help and get support from people like you.
Rybelsus News (Page 6)
ACG: GLP-1 RAs Tied to Lower Risk for Early-Onset Colorectal Cancer
FRIDAY, Nov. 1, 2024 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of...
Semaglutide Linked to Reduced Risk for Alzheimer Diagnosis in T2DM
FRIDAY, Nov. 1, 2024 – For patients with type 2 diabetes mellitus, semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic...
Ozempic, Wegovy Could Help Ease Knee Arthritis Pain
FRIDAY, Nov. 1, 2024 – The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found. People who received weekly injections of semaglutide – the active...
Semaglutide Beneficial for People With Obesity, Knee Osteoarthritis
THURSDAY, Oct. 31, 2024 – For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weight and pain related to knee osteoarthritis than placebo,...
Trends in Obesity Treatment Show Surge in GLP-1 RAs, Drop in Surgeries
TUESDAY, Oct. 29, 2024 – Among privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as antiobesity treatment from 2022 to 2023, with a...
Ozempic Curbs Kidney Disease in Obese People Without Diabetes
MONDAY, Oct. 28, 2024 – The weight-loss drug Ozempic can guard against kidney disease in obese people, a new study shows. Patients taking semaglutide – the active agent in Ozempic and Wegovy – had...
Duodenal ReCET Plus Semaglutide Can Prevent Need for Insulin in T2DM
THURSDAY, Oct. 24, 2024 – For patients with type 2 diabetes (T2D), duodenal recellularization via electroporation therapy (ReCET), which uses pulsed electric fields to induce natural cell death...
FDA Medwatch Alert: FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
October 2, 2024 -- The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection ...
Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity
TUESDAY, Oct. 15, 2024 – For adolescents with obesity, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is associated with a reduced risk for suicidal ideation or attempts, according to...
GLP-1 Weight-Loss Meds, Wegovy, Zepbound, Won't Raise Teens' Suicide Risk, May Even Lower It
MONDAY, Oct. 14, 2024 – As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise psychiatric risks, including the risk for suicide...
GLP-1 RA Use Linked to Retained Gastric Contents During Endoscopies
FRIDAY, Oct. 4, 2024 – Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic...
GLP-1 Weight-Loss Meds Could Interfere With Endoscopy, Colonoscopy
TUESDAY, Oct. 1, 2024 – Food left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy or colonoscopy. Now, research finds this scenario is...
Semaglutide Beneficial for Hidradenitis Suppurativa in Patients With Obesity
WEDNESDAY, Sept. 25, 2024 – For patients with obesity, the addition of semaglutide to standard hidradenitis suppurativa (HS) treatments yields improvement in quality of life and a reduction in...
Semaglutide May Lower Risk for Opioid Overdose in T2DM, Opioid Use Disorder
WEDNESDAY, Sept. 25, 2024 – For patients with type 2 diabetes (T2D) and opioid use disorder (OUD), semaglutide is associated with a significantly lower risk for opioid overdose compared with other...
Weight Reduction Varies for Patients Receiving Semaglutide, Liraglutide
FRIDAY, Sept. 13, 2024 – For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication active agent, dosage, treatment indication, and...